# Druggability Assessment of Tau Strain-Specific Therapeutic Hypotheses
## 1. Glial Glycocalyx Remodeling Therapy
**Druggability: MODERATE**
- **HSPG2/EXT1/EXT2**: Limited druggability. EXT1/EXT2 are intracellular enzymes requiring small molecule penetration
- **Chemical matter**: Heparanase inhibitors exist (SST0001, necuparanib) but are non-selective
**Existing compounds:**
- **SST0001 (roneparstat)**: Phase II trials for multiple myeloma (NCT02194985)
- **Necuparanib**: Phase I/II for pancreatic cancer (NCT02921022)
- **PG545**: Heparanase inhibitor, Phase I completed (NCT02042781)
**Competitive landscape:**
- Cantex Pharmaceuticals (CX-2029 heparanase inhibitor)
- Glycomimetics (GlycoEra program)
**Safety concerns:**
- Heparanase inhibition affects angiogenesis, wound healing
- Potential bleeding risk due to heparin-like activity
- Non-selective HSPG effects on growth factor signaling
**Timeline/Cost:**
- **3-5 years, $15-25M** for repurposing existing compounds
- **7-10 years, $50-80M** for novel EXT1/EXT2 modulators
## 2. Aquaporin-4 Polarization Rescue
**Druggability: LOW**
- **AQP4**: Notoriously difficult drug target (water channel)
- **SNTA1**: Intracellular scaffolding protein, poor druggability
**Existing compounds:**
- **TGN-020**: AQP4 inhibitor (research tool only)
- No clinical-stage AQP4 modulators exist
- No α-syntrophin targeting compounds available
**Competitive landscape:**
- Virtually non-existent for CNS AQP4 modulation
- Some activity in peripheral edema (Otsuka, AQP4 research program discontinued)
**Safety concerns:**
- AQP4 manipulation could worsen brain edema
- Essential role in water homeostasis
- Blood-brain barrier integrity issues
**Timeline/Cost:**
- **8-12 years, $100-150M** for novel AQP4 modulators (high risk)
- Currently no viable development path
## 3. Microglial Purinergic Reprogramming ⭐ MOST VIABLE
**Druggability: HIGH**
- **P2Y12**: Well-validated GPCR target
- **P2RX7**: Established ion channel target with multiple drug programs
**Existing compounds:**
- **P2Y12 antagonists**: Clopidogrel (Plavix), ticagrelor (Brilinta) - but CNS penetration limited
- **Brain-penetrant P2Y12**:
- **CZC24832** (research tool)
- **PSB-0739** (selective P2Y12 antagonist)
- **P2RX7 antagonists**:
- **JNJ-47965567** (Janssen, Phase II for depression, NCT02902601)
- **GSK1482160** (GSK, discontinued in Phase I)
- **AZD9056** (AstraZeneca, failed RA trials but CNS-active)
**Competitive landscape:**
- **Janssen**: Active P2RX7 program for psychiatric disorders
- **Pfizer**: P2RX7 research program
- **Roche**: Historical P2RX7 development (discontinued)
- **Evotec**: P2RX7 platform technology
**Safety concerns:**
- P2Y12 inhibition: bleeding risk (well-characterized from cardiology)
- P2RX7 antagonism: potential immunosuppression, infection risk
- Microglial function essential for brain homeostasis
**Timeline/Cost:**
- **4-6 years, $30-50M** for repurposing existing P2RX7 compounds
- **6-8 years, $60-100M** for novel brain-penetrant P2Y12 modulators
## 4. Ephrin-B2/EphB4 Axis Manipulation
**Druggability: MODERATE**
- **EphB4**: Receptor tyrosine kinase, established drug target class
- **EFNB2**: Cell surface protein, antibody targetable
**Existing compounds:**
- **EphB4 inhibitors**:
- **Dasatinib** (multi-kinase, includes EphB4, FDA-approved for CML)
- **NVP-BHG712** (Novartis, Phase I for solid tumors, NCT00788125)
- **EphB4 agonists**:
- **sEphB4-HSA** (Vasgene, Phase I for solid tumors, NCT01642342)
**Competitive landscape:**
- **VasGene Therapeutics**: EphB4-targeted therapies
- **HiberCell**: Ephrin receptor modulators
- Limited CNS-focused activity
**Safety concerns:**
- Ephrin signaling critical for vascular development
- Potential effects on angiogenesis and vascular integrity
- Developmental pathway activation in adults
**Timeline/Cost:**
- **5-7 years, $40-70M** for repurposing dasatinib or similar
- **8-10 years, $80-120M** for novel CNS-penetrant EphB4 modulators
## 5. Sphingolipid Metabolism Reprogramming
**Druggability: MODERATE-HIGH**
- **CERS2/CERS6**: Druggable enzymes with known inhibitors
- **SMPD1**: Established target with existing modulators
**Existing compounds:**
- **CERS inhibitors**:
- **Fumonisin B1** (mycotoxin, research tool, toxic)
- **2-hydroxyoleic acid** (Minerva, Phase II for brain tumors, NCT02759549)
- **SMPD1 modulators**:
- **Amitriptyline** (tricyclic antidepressant, SMPD1 inhibitor)
- **Imipramine** (tricyclic, SMPD1 activity)
- **ARC39** (acid sphingomyelinase inhibitor, preclinical)
**Competitive landscape:**
- **Minerva Neurosciences**: 2-hydroxyoleic acid program
- **Red Hill Biopharma**: Sphingolipid modulators
- **Apogenix**: Acid sphingomyelinase inhibitors
**Safety concerns:**
- Sphingolipid metabolism essential for cell membranes
- Potential effects on myelin and neuronal function
- Lysosomal storage disease-like phenotypes
**Timeline/Cost:**
- **3-5 years, $25-40M** for repurposing tricyclics
- **6-8 years, $50-80M** for selective CERS modulators
## 6. Complement C1q Subtype Switching
**Druggability: POOR**
- **C1QA/C1QC**: Secreted proteins, difficult to target selectively
- **C3AR1**: GPCR, potentially druggable but limited selectivity
**Existing compounds:**
- **General complement inhibitors**:
- **Eculizumab** (Soliris, Alexion, C5 inhibitor, $500K+/year)
- **Ravulizumab** (Ultomiris, Alexion, long-acting C5 inhibitor)
- **C3AR1 antagonists**:
- **SB290157** (research tool)
- No clinical-stage compounds
**Competitive landscape:**
- **Alexion/AstraZeneca**: Dominant in complement therapeutics
- **Achillion/Alexion**: Complement factor D inhibitors
- **Ra Pharma/UCB**: C5 inhibitors
**Safety concerns:**
- Complement inhibition increases infection risk (meningococcal)
- Essential innate immune function
- C1q subunit selectivity likely impossible
**Timeline/Cost:**
- **Not viable** - lack of selective targeting tools
- General complement inhibition: **$200-500K/patient/year**
## 7. Netrin-1 Gradient Restoration
**Druggability: POOR**
- **NTN1**: Large protein requiring gene/protein therapy
- **UNC5B/DCC**: Large extracellular domain receptors, poor small molecule targets
**Existing compounds:**
- **Netrin-1 protein therapy**: No clinical programs
- **Small molecule netrin modulators**: None exist
- **Gene therapy**: Theoretical but no programs
**Competitive landscape:**
- **Spinal Restoration Inc**: Netrin-1 for spinal cord injury (preclinical)
- No CNS-focused netrin programs for neurodegeneration
**Safety concerns:**
- Netrin-1 affects axonal guidance and synaptic function
- Potential developmental pathway reactivation
- CNS delivery challenges
**Timeline/Cost:**
- **Not currently viable** - no existing development tools
- Protein/gene therapy approach: **10+ years, $150-250M**
---
## OVERALL RECOMMENDATION
**Top Priority: Microglial Purinergic Reprogramming (P2RX7 focus)**
- Established target with clinical compounds
- Reasonable safety profile from existing trials
- Clear development path for CNS indications
- **Immediate next step**: License JNJ-47965567 or similar P2RX7 antagonist for tau studies
**Second Priority: Sphingolipid Metabolism**
- Repurpose existing tricyclic antidepressants as starting point
- Well-characterized safety profiles
- **Immediate next step**: Retrospective analysis of PSP/CBD patients on tricyclics
**Avoid: AQP4, Complement, Netrin-1**
- Poor druggability or questionable scientific premise
- No viable development path with current technology
**Research Priority: Glycocalyx and Ephrin**
- Require more basic research before therapeutic development
- Potential for future programs if mechanism validated